Lipids From proprotein convertase subtilisin / kexin type 9 to its inhibition : state-ofthe-art and clinical implications

Systematic Investigation and Research on Interventions and Outcomes (SIRIO) MEDICINE Research Network, Düsseldorf, Germany; Department of Internal Medicine, Division of Cardiology, Pulmonology and Vascular Medicine, Heinrich-Heine-University Düsseldorf, Moorenstr. 5, 40225 Düsseldorf, Germany; Collegium Medicum in Bydgoszcz, University of Nicolaus Copernicus, Toruń, Poland; Department of Emergency and Organ Transplantation (DETO), University of Bari, Bari, Italy; and Intensive Cardiac Care Unit, Cardiology Department, Hospital de la Santa Creu I Sant Pau, Barcelona, Spain

[1]  F. Mach,et al.  Stairs instead of elevators at the workplace decreases PCSK9 levels in a healthy population , 2015, European journal of clinical investigation.

[2]  E. Lonn,et al.  Association of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) With Cardiovascular Risk in Primary Prevention. , 2015 .

[3]  Jennifer G. Robinson,et al.  Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. , 2015, The New England journal of medicine.

[4]  J. Mehta,et al.  Cross-talk between LOX-1 and PCSK9 in vascular tissues. , 2015, Cardiovascular research.

[5]  B. Cariou,et al.  Patient and Physician Perspectives on Mode of Administration of the PCSK9 Monoclonal Antibody Alirocumab, an Injectable Medication to Lower LDL-C Levels. , 2015, Clinical therapeutics.

[6]  M. Krempf,et al.  ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia , 2015, European heart journal.

[7]  Malte Kelm,et al.  Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia: A Systematic Review and Meta-analysis. , 2015, Annals of internal medicine.

[8]  Cheng-gang Zhu,et al.  Proprotein convertase subtilisin-kexin type 9 as a biomarker for the severity of coronary artery disease , 2015, Annals of medicine.

[9]  S. Nishtar,et al.  Pro‐protein convertase subtilisin/kexin 9 concentrations correlate with coronary artery disease atheroma burden in a Pakistani cohort with chronic chest pain , 2015, International journal of clinical practice.

[10]  Improve-It Investigators.  Ezetimibe added to statin therapy after acute coronary syndromes , 2015 .

[11]  B. Balkau,et al.  The loss-of-function PCSK9 p.R46L genetic variant does not alter glucose homeostasis , 2015, Diabetologia.

[12]  J. Borén,et al.  Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment , 2015, European heart journal.

[13]  Jennifer G. Robinson,et al.  Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. , 2015, The New England journal of medicine.

[14]  Y. Zhang,et al.  Association of plasma small dense LDL cholesterol with PCSK9 levels in patients with angiographically proven coronary artery disease. , 2015, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[15]  Lesley Burgess,et al.  PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial , 2015, The Lancet.

[16]  F. Raal,et al.  Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial , 2015, The Lancet.

[17]  Jennifer G. Robinson,et al.  Efficacy and Safety of the PCSK9 Inhibitor Evolocumab (AMG 145) in Patients with Type 2 Diabetes , 2015 .

[18]  J. Borén,et al.  Prevention Familial hypercholesterolaemia in children and adolescents : gaining decades of life by optimizing detection and treatment , 2015 .

[19]  Deepak L. Bhatt,et al.  Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial. , 2014, American heart journal.

[20]  M. Reilly,et al.  PCSK9 is a critical regulator of the innate immune response and septic shock outcome , 2014, Science Translational Medicine.

[21]  J. Després,et al.  PCSK9 levels in abdominally obese men: association with cardiometabolic risk profile and effects of a one-year lifestyle modification program. , 2014, Atherosclerosis.

[22]  K. Kusuhara,et al.  Circulating PCSK9 levels correlate with the serum LDL cholesterol level in newborn infants. , 2014, Early human development.

[23]  J. Jukema,et al.  Alirocumab inhibits atherosclerosis, improves the plaque morphology, and enhances the effects of a statin[S] , 2014, Journal of Lipid Research.

[24]  T. Tuerxun,et al.  Correlation of PCSK9 Gene Polymorphism with Cerebral Ischemic Stroke in Xinjiang Han and Uygur Populations , 2014, Medical science monitor : international medical journal of experimental and clinical research.

[25]  B. Rutkowski,et al.  Elevated Circulating PCSK-9 Concentration in Renal Failure Patients is Corrected by Renal Replacement Therapy , 2014, American Journal of Nephrology.

[26]  U. Laufs,et al.  Risk prediction with proprotein convertase subtilisin/kexin type 9 (PCSK9) in patients with stable coronary disease on statin treatment. , 2014, Vascular pharmacology.

[27]  Jing Sun,et al.  Plasma PCSK9 levels are associated with the severity of coronary stenosis in patients with atherosclerosis. , 2014, International journal of cardiology.

[28]  C. Ballantyne,et al.  A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. , 2014, The New England journal of medicine.

[29]  R. Giugliano,et al.  Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trials. , 2014, Journal of the American College of Cardiology.

[30]  M. Taljaard,et al.  Chronic kidney disease on hemodialysis is associated with decreased serum PCSK9 levels. , 2014, Atherosclerosis.

[31]  U. Sinan.  Proprotein Convertase Subtilisin/Kexin Type 9 , 2014, Angiology.

[32]  A. Tonkin.  Faculty Opinions recommendation of Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. , 2014 .

[33]  R. Giugliano,et al.  Efficacy and Safety of Longer-Term Administration of Evolocumab (AMG 145) in Patients With Hypercholesterolemia: 52-Week Results From the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) Randomized Trial , 2014, Circulation.

[34]  H. Suryapranata,et al.  Safety and efficacy outcomes of first and second generation durable polymer drug eluting stents and biodegradable polymer biolimus eluting stents in clinical practice: comprehensive network meta-analysis , 2013, BMJ.

[35]  F. Raal,et al.  Effect of the Proprotein Convertase Subtilisin/Kexin 9 Monoclonal Antibody, AMG 145, in Homozygous Familial Hypercholesterolemia , 2013, Circulation.

[36]  Catherine Boileau,et al.  Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease , 2013, European heart journal.

[37]  N. Seidah,et al.  Regional distribution and metabolic effect of PCSK9 insLEU and R46L gene mutations and apoE genotype. , 2013, The Canadian journal of cardiology.

[38]  T. Lehtimäki,et al.  Beyond LDL-C lowering: distinct molecular sphingolipids are good indicators of proprotein convertase subtilisin/kexin type 9 (PCSK9) deficiency. , 2013, Atherosclerosis.

[39]  R. Kreis,et al.  Plasma PCSK9 concentrations during an oral fat load and after short term high-fat, high-fat high-protein and high-fructose diets , 2013, Nutrition & Metabolism.

[40]  Yuan-Lin Guo,et al.  Acute myocardial infarction in an 8-year old male child with homozygous familiar hypercholesterolemia: laboratory findings and response to lipid-lowering drugs. , 2013, Clinical laboratory.

[41]  J. Kastelein,et al.  The PCSK9 decade , 2012, Journal of Lipid Research.

[42]  Zhisheng Jiang,et al.  PCSK9 siRNA suppresses the inflammatory response induced by oxLDL through inhibition of NF-κB activation in THP-1-derived macrophages. , 2012, International journal of molecular medicine.

[43]  P. Snyder,et al.  Regulation of Epithelial Sodium Channel Trafficking by Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)* , 2012, The Journal of Biological Chemistry.

[44]  A. Prat,et al.  Gene Inactivation of Proprotein Convertase Subtilisin/Kexin Type 9 Reduces Atherosclerosis in Mice , 2012, Circulation.

[45]  F. Cipollone,et al.  Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels. , 2012, Atherosclerosis.

[46]  E. Braunwald,et al.  A tale of coronary artery disease and myocardial infarction. , 2012, The New England journal of medicine.

[47]  P. Ridker,et al.  Rosuvastatin, proprotein convertase subtilisin/kexin type 9 concentrations, and LDL cholesterol response: the JUPITER trial. , 2012, Clinical chemistry.

[48]  P. Kolh,et al.  ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). , 2011, European heart journal.

[49]  Tao Yang,et al.  Serum PCSK9 is associated with multiple metabolic factors in a large Han Chinese population. , 2010, Atherosclerosis.

[50]  J. Horton,et al.  Fasting reduces plasma proprotein convertase, subtilisin/kexin type 9 and cholesterol biosynthesis in humans , 2010, Journal of Lipid Research.

[51]  S. Kathiresan,et al.  Effects of PCSK9 genetic variants on plasma LDL cholesterol levels and risk of premature myocardial infarction in the Italian population , 2010, Journal of Lipid Research.

[52]  M. Krempf,et al.  Association between plasma PCSK9 and gamma-glutamyl transferase levels in diabetic patients. , 2010, Atherosclerosis.

[53]  Børge G Nordestgaard,et al.  PCSK9 R46L, low-density lipoprotein cholesterol levels, and risk of ischemic heart disease: 3 independent studies and meta-analyses. , 2010, Journal of the American College of Cardiology.

[54]  E. Levy,et al.  Plasma PCSK9 is associated with age, sex, and multiple metabolic markers in a population-based sample of children and adolescents. , 2009, Clinical chemistry.

[55]  Jonathan C. Cohen,et al.  Genetic and metabolic determinants of plasma PCSK9 levels. , 2009, The Journal of clinical endocrinology and metabolism.

[56]  K. Feingold,et al.  Inflammation stimulates the expression of PCSK9. , 2008, Biochemical and biophysical research communications.

[57]  S. Humphries,et al.  Genetic causes of familial hypercholesterolaemia in patients in the UK: relation to plasma lipid levels and coronary heart disease risk , 2006, Journal of Medical Genetics.

[58]  Jonathan C. Cohen,et al.  Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. , 2006, The New England journal of medicine.

[59]  M. Krempf,et al.  Hepatic PCSK9 Expression Is Regulated by Nutritional Status via Insulin and Sterol Regulatory Element-binding Protein 1c* , 2006, Journal of Biological Chemistry.

[60]  C. Junien,et al.  Novel mutations of the PCSK9 gene cause variable phenotype of autosomal dominant hypercholesterolemia , 2005, Human mutation.

[61]  J. Weissenbach,et al.  Mutations in PCSK9 cause autosomal dominant hypercholesterolemia , 2003, Nature Genetics.